Combination of bevacizumab plus irinotecan in recurrent malignant gliomas (MG): A retrospective study of efficacy and safety

被引：0
|
作者：
Gil Gil, M. J., Sr.
Martinez-Garcia, M.
Reynes, G.
Costas, E.
Fernandez-Chacon, C.
Pernas, S.
Benavides, M.
Herrero, A.
Perez-Martin, J.
Balana, C.
机构：
[1] Inst Catala Oncol, Barcelona, Spain
[2] Hosp Univ La Fe, Valencia, Spain
[3] MD Anderson Espana Int, Madrid, Spain
[4] Hosp Carlos Haya, Malaga, Spain
[5] Hosp Miguel Servet, Zaragoza, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13011
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas
    Wagner, S. A.
    Desjardins, A.
    Reardon, D. A.
    Marcello, J.
    Herndon, J. E., II
    Quinn, J. A.
    Rich, J. N.
    Sathornsumetee, S.
    Friedman, H. S.
    Vredenburgh, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
    Friedman, Henry S.
    Prados, Michael D.
    Wen, Patrick Y.
    Mikkelsen, Tom
    Schiff, David
    Abrey, Lauren E.
    Yung, W. K. Alfred
    Paleologos, Nina
    Nicholas, Martin K.
    Jensen, Randy
    Vredenburgh, James
    Huang, Jane
    Zheng, Maoxia
    Cloughesy, Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4733 - 4740
  • [43] OFF-LABEL USE OF BEVACIZUMAB IN ASSOCIATION WITH IRINOTECAN FOR PEDIATRIC GLIOMAS: EFFICACY AND SAFETY
    Cuinet, Aurelie
    Pasqualini, Claudia
    Boutard, Patrick
    Lejars, Odile
    Schneider, Pascale
    Dufour, Christelle
    Geoerger, Birgit
    Grill, Jacques
    PEDIATRIC BLOOD & CANCER, 2010, 55 (05) : 926 - 926
  • [44] Efficacy and safety of bevacizumab combined with temozolomide in the treatment of recurrent malignant gliomas and its influence on serum tumor markers
    Lei, Jun
    Zhou, Zhi
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (12): : 13886 - 13893
  • [45] Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer
    M. Degirmenci
    B. Karaca
    G. Gorumlu
    R. Durusoy
    G. Demir Piskin
    M. T. Bozkurt
    Y. Cirak
    D. Tunali
    B. Karabulut
    U. A. Sanli
    R. Uslu
    Medical Oncology, 2010, 27 : 585 - 591
  • [46] Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer
    Degirmenci, M.
    Karaca, B.
    Gorumlu, G.
    Durusoy, R.
    Piskin, G. Demir
    Bozkurt, M. T.
    Cirak, Y.
    Tunali, D.
    Karabulut, B.
    Sanli, U. A.
    Uslu, R.
    MEDICAL ONCOLOGY, 2010, 27 (03) : 585 - 591
  • [47] Bevacizumab and Recurrent Malignant Gliomas: A European Perspective
    Wick, Wolfgang
    Weller, Michael
    van den Bent, Martin
    Stupp, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : E188 - E189
  • [48] The Efficacy and Safety of Irinotecan Plus Temozolomide and Vincristine in Neuroblastoma with Brain Recurrence: A Retrospective Study
    Wang, J.
    Zhen, Z.
    Zhu, S.
    Lian, Z.
    Lu, S.
    Sun, F.
    Huang, J.
    Zhang, Y.
    Sun, X.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S213 - S214
  • [49] Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas
    Goli, K. J.
    Desjardins, A.
    Herndon, J. E., II
    Rich, J. N.
    Reardon, D. A.
    Quinn, J. A.
    Sathornsumetee, S.
    Bota, D. A.
    Friedman, H. S.
    Vredenburgh, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] EFFICACY AND SAFETY OF BEVACIZUMAB COMBINATION CHEMOTHERAPY FOR RECURRENT CERVICAL CANCER
    Kusakabe, M.
    Tanikawa, M.
    Oda, K.
    Nagasaka, K.
    Miyamoto, Y.
    Sone, K.
    Mori, M.
    Tsuruga, T.
    Matsumoto, Y.
    Osuga, Y.
    Fujii, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 318 - 318
12345